VITA 34 International AG: VITA 34 revises sales forecast for 2009 / Profit is expected to break even as planned

VITA 34 International AG / Change in Forecast

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

Leipzig, December 16, 2008 – VITA 34 International AG (ISIN DE000A0BL849),
the parent company of the leading private umbilical cord blood bank in the
German-speaking countries VITA 34, is reducing its sales forecast for the
2009 financial year. The profit target of at least breaking even with EBIT
will remain unchanged due to the company’s good scalability. VITA 34 will
also adjust the cost structure according to the coming market situation.
The sales forecast has been reduced as a result of the unexpectedly slow
development in storing umbilical cord blood in German speaking countries.
Due to the current challenging economic situation it is also difficult to
judge exactly how consumer behaviour will develop in the coming months.
Sales for 2009 will be significantly lower than the EUR 28 million
previously forecast. In order to become less dependent on developments in
the German market and enhance additional growth potential, VITA 34 is going
to be entering other European markets. One example for this is the
especially positive cooperation with the Spanish partner Secuvita.

VITA 34 is anticipating sales of EUR 15 million for the 2008 financial
year, which would be in line with the revised sales forecast of EUR 15 to
16 million made in July. VITA 34 also expects to achieve the planned result
which shows an EBIT of EUR -2.5 million.

Press/Investor Relations:
Axel Mühlhaus
Dr. Sönke Knop
edicto GmbH
Zeißelstraße 19
D-60318 Frankfurt
Tel.:+49 (069) 90550550
Fax: +49 (069) 90550577

16.12.2008  Financial News transmitted by DGAP
Language:     English
Issuer:       VITA 34 International AG
              Deutscher Platz 5a
              04103 Leipzig
Phone:        +49(0341)48792-40
Fax:          +49(0341)48792-39
ISIN:         DE000A0BL849
WKN:          A0BL84
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, Hamburg, München, Stuttgart
End of News                                     DGAP News-Service